Birch pollen-specific immunoglobulin E (Birch sIgE) (Birch sIgE)

Birch pollen-specific immunoglobulin E (IgE) is a specialized class of antibody produced by the immune system in response to allergens found in birch pollen, most notably the major allergen Bet v 1 (UniProt, 2024). In sensitized individuals, these IgE molecules circulate in the blood and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to birch pollen, the allergens cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators such as histamine and leukotrienes (World Allergy Organization, 2022). This process is the primary driver of clinical symptoms associated with birch pollen allergy, including allergic rhinitis, conjunctivitis, and exacerbations of allergic asthma. Therapeutic targeting of these antibodies involves monoclonal antibodies like Omalizumab, which sequester free IgE to prevent receptor binding (NCBI, 2023). Additionally, allergen-specific immunotherapy (AIT) aims to modulate the immune system to reduce the production of these specific IgE antibodies while increasing protective IgG4 levels. Monitoring levels of birch-specific IgE is a standard diagnostic practice for identifying patients who will benefit from these targeted therapies. The interaction between these antibodies and their receptors represents a critical checkpoint in the allergic cascade and a major focus for drug development in respiratory and dermatological conditions.

Other names

Bet v 1-specific IgEBirch-specific IgEAnti-birch pollen IgEBirch pollen sIgE

Binding to the Fc region of free IgE to prevent its interaction with high-affinity FcεRI receptors on mast cells and basophils, thereby inhibiting the allergic cascade (NCBI, 2023).